CD274 and neoplasm: Univariate survival analysis of Siglec-15/PD-L1 in each tumor part showed that TC-Siglec-15+ patients had worse DFS (HR, 6.76; 95%CI, 2.19–20.93; p < 0.001), and Mφ-Siglec-15+ patients had worse DFS (HR, 2.93; 95% CI, 1.25–6.91; p = 0.01), TC-PD-L1 (HR, 5.36; 95%CI, 2.18–13.19; p < 0.001) and NTC-PD-L1 (HR, 6.15; 95% CI, 2.40–15.76; p < 0.001) was also unfavorable for DFS (Fig. 2E–H).